These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 29407054)
1. Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. Lovre D; Shah S; Sihota A; Fonseca VA Endocrinol Metab Clin North Am; 2018 Mar; 47(1):237-257. PubMed ID: 29407054 [TBL] [Abstract][Full Text] [Related]
2. Statin use in patients with diabetes and kidney disease: the Japanese experience. Koya D; Campese VM J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468 [TBL] [Abstract][Full Text] [Related]
3. Is lipid management effective for all stages of CKD? Ku E; Campese V Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543 [TBL] [Abstract][Full Text] [Related]
4. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. Athyros VG; Tziomalos K; Karagiannis A Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619 [TBL] [Abstract][Full Text] [Related]
5. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease. Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176 [TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of treatment for dyslipidemia in CKD]. Ikemori A; Kimura K Nihon Jinzo Gakkai Shi; 2013; 55(7):1287-94. PubMed ID: 24288965 [No Abstract] [Full Text] [Related]
7. Diabetes-Related Dyslipidemia and Cardiovascular Events. Fonseca VA; Lovre D Am J Med Sci; 2017 Aug; 354(2):103-104. PubMed ID: 28864365 [No Abstract] [Full Text] [Related]
10. Dyslipidemia in Patients with Kidney Disease. Thobani A; Jacobson TA Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749 [TBL] [Abstract][Full Text] [Related]
11. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. Branch M; German C; Bertoni A; Yeboah J J Diabetes Complications; 2019 Jul; 33(7):468-472. PubMed ID: 31088728 [TBL] [Abstract][Full Text] [Related]
12. [Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment topics: I. Pathophysiology, diagnosis and treatment: 9. Dyslipidemia]. Arai H Nihon Naika Gakkai Zasshi; 2013 Apr; 102(4):890-4. PubMed ID: 23772503 [No Abstract] [Full Text] [Related]
13. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK; Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217 [TBL] [Abstract][Full Text] [Related]
14. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists. Serowik TC; Pantalone KM J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061 [TBL] [Abstract][Full Text] [Related]
15. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations. Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818 [TBL] [Abstract][Full Text] [Related]